Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2019 08:31 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

-- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to...
October 30, 2019 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019

BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
October 18, 2019 12:32 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BOSTON, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
October 15, 2019 23:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
October 15, 2019 16:18 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment...
September 25, 2019 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Provides Update on Research and Development Programs

-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584...
September 09, 2019 07:30 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant...
September 03, 2019 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
August 07, 2019 07:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

-- Both studies met primary and all key secondary endpoints with statistically significant and clinically meaningful results in reductions of weight and hunger -- -- Rhythm on track to complete...
July 29, 2019 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results

-- Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity -- -- Announced positive opinion by EMA on Orphan Drug Designation for setmelanotide for the...